查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
阿达木单抗全球市场 - 2022-2029
市场调查报告书
商品编码
1140667

阿达木单抗全球市场 - 2022-2029

Global Adalimumab Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年阿达木单抗市场价值 38.294 亿美元。预计在预测期内（2022-2029 年）将以 5.2% 的复合年增长率增长。

阿达木单抗是一种治疗类风湿性关节炎 (RA)、幼年特发性关节炎 (JIA)、银屑病关节炎 (PsA)、强直性脊柱炎 (AS)、克罗恩病 (CD) 和斑块型银屑病 (Ps) 的治疗药物。名称“修美乐”。阿达木单抗是一种重组人 IgG1 单克隆抗体，靶向肿瘤坏死因子 (TNF)，通过与肿瘤坏死因子结合发挥作用。它通过结合肿瘤坏死因子 (TNF) 并抑制其与细胞表面 TNF 受体 p55 和 p75 的相互作用而起作用。裂解表达表面肿瘤坏死因子的细胞。有效调节由 TNF 诱导或调节的生物反应，这些反应涉及与白细胞迁移有关的粘附分子水平的变化。

阿达木单抗是使用噬菌体展示技术开发的具有人源重炼和轻链可变区以及人 IgG1:k 恆定区的抗体。该抗体是通过重组 DNA 技术在哺乳动物细胞表达系统中产生的。该产品以一次性预填充笔或一次性 1 mL 填充玻璃注射器的形式提供。

市场动态

自身免疫性疾病患病率上升推动市场增长

由于自身免疫性疾病的患病率上升，对阿达木单抗的需求增加推动了市场。根据国家干细胞基金会 (NSCF) 的数据，据说世界上大约 4% 的人口受到一种或另一种自身免疫性疾病的影响。类风湿性关节炎、强直性脊柱炎、克罗恩病、银屑病关节炎和寻常型银屑病是最常见的自身免疫性疾病。据美国银屑病基金会称，世界上大约 2% 到 3% 的人口，即 1.25 亿人患有银屑病。大约 30% 的银屑病患者会发展为银屑病关节炎，这是一种导致关节畸形和残疾的慢性炎症性关节炎。强直性脊柱炎影响全世界约 0.1% 至 1.4% 的人。男性比女性更常见。根据关节炎基金会的数据，大约 80% 的人会在 30 岁之前出现强直性脊柱炎的症状。 45 岁及以上的所有患者中约有 5% 会发展为强直性脊柱炎。

完善阿达木单抗报销制度促进市场增长

扩大阿达木单抗的保险范围将推动市场增长。阿达木单抗的覆盖率约为 99%，包括 Medicare Part D 和 Medicaid 患者。中国监管机构还将阿达木单抗列入国家医保药品目录（NRDL）。中国监管机构已将阿达木单抗与製药公司的价格平均降低了 61%。

与使用阿达木单抗相关的副作用阻碍市场增长

与使用阿达木单抗相关的副作用正在阻碍市场。在患者中可能会观察到一些副作用，包括噁心、腹痛、高脂血症、血尿、高胆固醇血症、背痛、皮疹、头痛和高血压。在阿达木单抗的注射部位观察到发红、肿胀和疼痛。它还增加了真菌、细菌和病毒感染在全身发展和传播的风险。由细菌、分枝桿菌、侵入性真菌、病毒、寄生虫等引起的机会性感染，如曲霉菌病、芽生菌病、念珠菌病、球孢子菌病、组织胞浆菌病、军团菌病、李斯特菌病、肺孢子菌病、肺结核病等。接受患者的认可。

COVID-19 影响分析

阿达木单抗的全球市场受到 COVID-19 疫情的极大刺激。多个研究机构、组织和公司专注于评估阿达木单抗治疗 COVID-19 的潜力。针对 COVID-19 的阿达木单抗的研发活动也在增加。 COVID-19 患者在使用抗 TNF 药物治疗炎症性肠病和炎症性关节炎时不太可能住院。抗 TNF 疗法可有效中和 TNF，TNF 是细胞因子反应的关键组成部分，是 COVID-19 有害高炎症阶段的一部分。因此，我们专注于进行临床试验，以测试阿达木单抗对 COVID-19 患者的疗效和安全性。例如，2020 年 10 月，英国牛津大学的研究人员计划启动一项新的临床试验，评估阿达木单抗在居家社区护理环境中治疗 COVID-19 患者的疗效。临床试验 (AVID-CC) 将由牛津临床试验和研究单位 (OCTRU) 领导，并将招募多达 750 名来自社区护理院的患者。

流行病学

2019 年全球疾病负担、伤害和风险因素研究 (GBD) 估计，2019 年类风湿性关节炎 (RA) 的患病率为 326 万。女性受到影响的可能性是男性的两到三倍。大约有 12 名女性和 20 名男性中有 1 名在其一生中会患上炎症性自身免疫性风湿病。根据 Giegerich E 等 2018 年的数据，2017 年克罗恩病的诊断患病率在亚太低收入地区为每 10 万人 6 人，在高收入亚太地区为每 10 万人 46 人，在欧洲为每 10 万人 46 人。说，北美每10万人中有133例，每10万人中有210例。克罗恩病的确诊患病率在 40-54 岁的人群中最高。强直性脊柱炎患病率欧洲为23.8/万，亚洲为16.7/万，北美为31.9/万，拉丁美洲为10.2/万，非洲为1万，人均确诊7.4。

市场细分

预计阿达木单抗市场将占类风湿关节炎的最大份额

按疾病类型分为类风湿关节炎、银屑病关节炎、克罗恩病、溃疡性结肠炎等。预计类风湿关节炎部分将占据阿达木单抗治疗市场的最大份额。类风湿性关节炎是最常见的自身免疫性关节炎，影响关节、结缔组织、肌肉、肌腱和纤维组织。类风湿性关节炎的特征是关节疼痛、僵硬、肿胀和关节运动减少。它会导致手腕和手脚小关节疼痛和肿胀。类风湿性关节炎会干扰患者的活动能力并导致永久性关节损伤。类风湿性关节炎的患病率在世界范围内呈上升趋势。根据世界卫生组织 (WHO) 的数据，类风湿性关节炎的患病率在全球范围内为 0.3% 至 1%。女性也比男性更常见。

从分销渠道来看，预计医院药房在预测期内将实现高增长

市场按分销渠道分为医院药房、零售药房、在线药房等。由于医院药房中阿达木单抗的高可用性，预计医院药房将显示出最高的市场增长。医院越来越多地使用阿达木单抗治疗自身免疫性疾病和皮肤病。阿达木单抗可有效减轻与某些疾病相关的疼痛和肿胀。

区域分析

北美占阿达木单抗全球市场的最大份额。

由于类风湿性关节炎 (RA)、银屑病关节炎、克罗恩病、斑块状银屑病和溃疡性结肠炎的高发病率，北美地区在 2021 年占全球阿达木单抗市场的最大份额。根据美国银屑病基金会的数据，美国约有 100 万人患有银屑病关节炎。根据美国国家关节炎、肌肉骨骼和皮肤病研究所的数据，斑块型银屑病是最常见的银屑病形式，在美国影响了大约 670 万成年人。根据美国国立卫生研究院的数据，美国克罗恩病的患病率为每 10 万人 201 人。

由于对阿达木单抗的优惠报销，美国拥有最高的市场份额。有多个市场参与者正在开发阿达木单抗。研究阿达木单抗在类风湿性关节炎 (RA)、银屑病关节炎、克罗恩病和溃疡性结肠炎以外的适应症方面的潜力的研发活动也在增加。预计在预测期内，先进的医疗保健设施和基础设施将推动市场发展。

预计亚太地区将在预测期内以最快的复合年增长率增长

由于不健康的生活方式、日常生活压力和免疫系统功能障碍导致自身免疫性疾病患病率增加，据估计，亚太地区是全球阿达木单抗市场增长最快的地区。 .预计不断增长的老年人口也将对市场产生积极影响。联合国报告称，印度约有 8700 万 65 岁及以上的人口。对医疗设施和基础设施的投资也在增加。提高对自身免疫性疾病的认识，对市场产生积极影响。

由于对生物仿製药的有利法规，阿达木单抗生物仿製药正在获得批准。例如，2020年9月，InnoVent Biologics获得中国国家药品监督管理局（NMPA）批准的类风湿关节炎（RA）重组人抗TNF-α单克隆抗体製剂Surinno（阿达木单抗注射液）获批用于治疗强直性脊柱炎和牛皮癣。由于国内收入和购买力的提高，预计在预测期内对阿达木单抗的需求将增加。

竞争格局。

阿达木单抗市场分散，公司众多。 AbbVie Inc、Amgen Inc、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company, Ltd、F. Hoffmann-La Roche Ltd、Glenmark Pharmaceuticals、Novartis AG 和 Pfizer Inc 将成为拥有重要市场份额的主要参与者。公司正在采取多种增长战略，例如产品发布、收购、合併、合作伙伴关係和许可，以增加其市场占有率。例如：

合併与合作。

2020 年 9 月，Sensyne Health plc 与牛津大学建立合作伙伴关係，开展一项临床试验，以评估阿达木单抗治疗 COVID-19 的效果。根据协议条款， Sensyne 将为抗 TNF 药物阿达木单抗预防 COVID-19引起的呼吸衰竭的 AVID-CC 2期临床试验提供远程数据收集和分析软件。

产品发布和批准

2021 年 2 月 24 日，艾伯维获得美国食品药品监督管理局 (FDA) 对 HUMIRA（阿达木单抗）的批准。 HUMIRA 是一种皮下生物製剂，适用于 5 岁及以上患有中度至重度活动性溃疡性结肠炎的儿科患者。

2021 年 5 月 5 日，加拿大安进公司推出了引用 Humira 的阿达木单抗生物类似药 (Amjevita)。该生物仿製药产品适用于参考产品的所有适应症。这种amjevita包括类风湿性关节炎、银屑病关节炎、多关节幼年特发性关节炎、克罗恩病、强直性脊柱炎和溃疡性结肠炎。现在在加拿大有售。

2019 年 11 月 18 日，辉瑞公司宣布已获得美国食品和药物管理局 (FDA) 的批准，将 ABRILADA (adalimumab-afzb) 作为 Humira (adalimumab) 的生物仿製药。 Abrilah 用于治疗患有类风湿性关节炎、银屑病关节炎、强直性脊柱炎、幼年特发性关节炎、成人克罗恩病、溃疡性结肠炎和寻常型银屑病的特定患者。

明白了。

2020 年 5 月，AbbVie 收购了 Allergan plc。

与

合作。

2020 年 3 月，Albotech HF 与 DKSH 就艾伯维（AbbVie）的 Humira（阿达木单抗）生物仿製药 AVT02在亚太地区（APAC）市场的商业化签订了独家许可协议。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按疾病类型划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 自身免疫性疾病的患病率不断上升
      • 优惠的保险报销范围
    • 限制因素
      • 与使用阿达木单抗相关的副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疾病类型

  • 类风湿性关节炎 (RA)
  • 银屑病关节炎 (PsA)
  • 克罗恩病 (CD)
  • 强直性脊柱炎 (AS)
  • 斑块状银屑病 (Ps)
  • 溃疡性结肠炎
  • 其他

第 8 章按销售渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • 艾伯维公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cadila Healthcare Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Glenmark Pharmaceuticals
  • Hetero Healthcare Limited
  • Novartis AG
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Mylan N.V
  • Emcure Pharmaceuticals Ltd.
  • Cipla Inc.
  • Reliance Life Sciences
  • Samsung Bioepis Co Ltd.
  • Terumo Corp.
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.（LIST NOT EXHAUSTIVE）

第12章 DataM

简介目录
Product Code: DMPH2788

Market Overview

Adalimumab market was valued at USD 3829.40 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Adalimumab is approved under the brand name Humira for the treatment of Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn's Disease (CD), and Plaque Psoriasis (Ps). Adalimumab is a recombinant human IgG 1 monoclonal antibody that targets tumour necrosis factor (TNF). It acts by binding to the tumour necrosis factor (TNF) and inhibiting its interaction with the p55 and p75 cell surface TNF receptors. It lyses surface tumour necrosis factor expressing cells. It is effective in modulating the biological responses induced or regulated by TNF involving the changes in the levels of adhesion molecules responsible for leukocyte migration.

Adalimumab is developed by using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system. It is supplied as either a single-use, prefilled pen or as a single-use, 1 mL filled glass syringe.

Market Dynamics

Rising Prevalence of Autoimmune Disorders is Driving the Growth of the Market

The market is driven by the increasing demand for adalimumab with the increasing prevalence of autoimmune diseases. According to the National Stem Cell Foundation (NSCF), approximately 4% of the world's population is suffering from one autoimmune disease. Rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis, plaque psoriasis, and others are the most common autoimmune diseases. According to the National Psoriasis Foundation, approximately 2% to 3% of the global population i.e., 125 million people are suffering from Psoriasis worldwide. Approximately, 30% of patients with psoriasis develop psoriatic arthritis, chronic inflammatory arthritis that leads to joint deformations and disability. Ankylosing spondylitis affects around 0.1% and 1.4% of people worldwide. It is most frequent in men in comparison to women. According to the Arthitis Foundation, around 80% of people develops the symptoms of ankylosing spondylitis in the age group at or before age of 30 years. Around, 5% of patients would develop ankylosing spondylitis in the age group of 45 or older.

Favorable Reimbursement Coverage for Adalimumab is Boosting the Market Growth

The better availability of the reimbursement coverage for adalimumab shall stimulate market growth. Around, 99% of national commercial, Medicare Part D, and Medicaid patients cover the adalimumab. Chinese regulators had also included adalimumab in the country's National Reimbursement Drug List (NRDL). Chinese regulators provide with an average of 61% in price cuts of adalimumab with pharma companies.

Adverse Effects Associated with the use of Adalimumab is Hampering the Market Growth

The market is hindered by the adverse effects associated with the use of the adalimumab. Several adverse effects such as nausea, abdominal pain, hyperlipidemia, hematuria, hypercholesterolemia, back pain, rash, headache, hypertension, and others are observed among the patients. Redness, swelling or pain is observed at the site of injection of the adalimumab. It also increases the risk of developing a fungal, bacterial, and viral infection that can spread through the body. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been observed among the patients treated with adalimumab.

COVID-19 Impact Analysis

The global adalimumab market has received immense impetus from the COVID-19 pandemic, as several institutes, organizations, and companies are focussing on evaluating the potential of adalimumab for the treatment of the COVID-19. There is increasing research and development activities for adalimumab for the COVID-19. It has been observed that the COVID-19 patients who had administered the anti-TNF therapies for the treatment of inflammatory bowel disease and inflammatory arthritis were less likely to be hospitalised. The anti-TNF therapies are effective in neutralizing the TNF, a major component of the cytokine response part of the damaging excess inflammatory phase of COVID-19. Therefore, institutes and organizations are focussing on conducting clinical trials for examining the efficacy and safety of adalimumab among patients with COVID-19. For instance, in October 2020, Researchers at the University of Oxford in the United Kingdom had planned to initiate a new clinical trial to evaluate the effectiveness of the adalimumab for the treatment of the COVID-19 patients in community care settings, primarily in care homes. The clinical trial i.e., AVID-CC would be led by the Oxford Clinical Trials Research Unit (OCTRU) and would enroll up to 750 patients from community care homes.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the estimation that the prevalence of Rheumatoid Arthritis (RA) was resulted in 3.26 million in 2019. Women are two to three times as likely to be affected in comparison to men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Market Segment Analysis

The Rheumatoid Arthritis segment is expected to hold the largest share in the Adalimumab market

By disease type, the market is classified as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and others. The rheumatoid arthritis segment is anticipated to hold the largest share in the adalimumab treatment market. Rheumatoid arthritis is the most common autoimmune arthritis that affects the joints, connective tissues, muscle, tendons, and fibrous tissues. It is characterized by joint pain, stiffness, swelling and decreased movement of the joints. It causes pain and swelling in the wrist and small joints of the hand and feet. Rheumatoid Arthritis can hamper the patient's mobility and lead to permanent joint damage. The prevalence of rheumatoid arthritis is increasing worldwide. According to the World Health Organization (WHO), the prevalence of rheumatoid arthritis ranges between 0.3% and 1% across the globe. It is most frequent among women in comparison to men.

By Distribution Channel, Hospital Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified based on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies are segmented to have the highest market growth due to the high availability of the adalimumab in the hospital pharmacies. There is a growing usage of the adalimumab for the treatment of autoimmune and skin disorders in hospitals. Adalimumab is effective in reducing the pain, and swelling associated with several disorders.

Geographical Analysis

North America region holds the largest market share global Adalimumab market

North America region is dominating the global adalimumab market accounted for the largest market share in 2021 owing to the high prevalence of Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, Plaque Psoriasis, and Ulcerative Colitis. According to the National Psoriasis Foundation, around one million people are being affected by Psoriatic Arthritis in the United States. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Plaque Psoriasis is the most frequent form of psoriasis that affects around 6.7 million adults in the United States. As per the National Institute of Health, the prevalence of Crohn's Disease was 201 per 100,000 in the United States.

The United States accounts for the highest market share due to the availability of favorable reimbursement coverage for adalimumab. There is a presence of several market players developing adalimumab. There is increasing research and development activities for examining the potential of adalimumab for the treatment of other indications apart from Rheumatoid Arthritis (RA), Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis. The availability of advanced healthcare facilities and infrastructure shall stimulate the market over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global adalimumab market owing to the increasing prevalence of autoimmune diseases with the increasing adoption of unhealthy lifestyles, stress in daily life & immune system malfunction. The growing elder population shall have a positive impact on the market. According to the United Nations Report, there were around 87 million of the population of age-group 65 years or over in India. There is increasing investment for the improvement of the healthcare facilities & infrastructure. There is increasing awareness that autoimmune diseases shall have a positive impact on the market.

There is an increase in the approval of the biosimilars of adalimumab due to the presence of favorable regulatory policies for biosimilars. For instance, in September 2020, Innovent Biologics, Inc. had received the approval for Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug from the National Medical Products Administration (NMPA) of China for the treatment of Rheumatoid Arthritis (RA), ankylosing spondylitis and psoriasis in China. The increasing domestic income and purchasing power of people shall boost the demand for adalimumab over the forecasted period.

Competitive Landscape:

The adalimumab market studied is a fragmented market with the presence of a large number of market players. AbbVie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Ltd, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals, Novartis AG, and Pfizer Inc are the major market players with the significant market share. Companies are adopting several growth strategies such as product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers & Collaborations:

In September 2020, Sensyne Health plc had entered into the collaboration with the University of Oxford for conducting the clinical trial for evaluating the adalimumab for the treatment of COVID-19. Under the terms of the agreement, Sensyne would provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19

Product Launch & Approvals:

On 24th February 2021, AbbVie. had received approval for HUMIRA (adalimumab) from the United States Food and Drug Administration (FDA). The HUMIRA is the subcutaneous biologic treatment for pediatric patients 5 years of age and older with moderately to severely active ulcerative colitis.

On 5th May 2021, Amgen Canada launched Its adalimumab biosimilar (Amgevita), referencing Humira. The biosimilar product is available for all indications of the reference product. This Amgevita includes rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Crohn's disease, ankylosing spondylitis, and ulcerative colitis. It is now available in Canada.

On 18th November 2019, Pfizer Inc. announced that it received approval from the United States Food and Drug Administration (FDA) for ABRILADA (adalimumab-afzb) as a biosimilar to Humira (adalimumab). The ABRILADA is used to treat certain patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

Acquisition:

In May 2020, AbbVie had acquired the Allergan plc

Partnership:

In March 2020, Alvotech HF had entered into an exclusive license partnership with DKSH for the commercialization of AVT02, a biosimilar to AbbVie's HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Autoimmune Disorders
      • 4.1.1.2. Favorable Reimbursement Coverage
      • 4.1.1.3. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. Adverse Effects Associated with the Use of Adalimumab
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Rheumatoid Arthritis (RA)*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Psoriatic Arthritis (PsA)
    • 7.3.3. Crohn's Disease (CD)
    • 7.3.4. Ankylosing Spondylitis (AS)
    • 7.3.5. Plaque Psoriasis (Ps)
    • 7.3.6. Ulcerative Colitis
    • 7.3.7. Others

8. By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospitals Pharmacies*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. The Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. AbbVie Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Amgen Inc.
  • 11.3. Boehringer Ingelheim International GmbH
  • 11.4. Bristol-Myers Squibb Company
  • 11.5. Cadila Healthcare Ltd.
  • 11.6. F. Hoffmann-La Roche Ltd.
  • 11.7. Glenmark Pharmaceuticals
  • 11.8. Hetero Healthcare Limited
  • 11.9. Novartis AG
  • 11.10. Pfizer Inc.
  • 11.11. Torrent Pharmaceuticals Ltd.
  • 11.12. Mylan N.V
  • 11.13. Emcure Pharmaceuticals Ltd.
  • 11.14. Cipla Inc.
  • 11.15. Reliance Life Sciences
  • 11.16. Samsung Bioepis Co Ltd.
  • 11.17. Terumo Corp.
  • 11.18. Fujifilm Kyowa Kirin Biologics Co. Ltd.(LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us